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Breast-conserving surgery involves completely excising the tumour while limiting the amount of normal tissue removed, which is
technicallychallengingtoachieve,especiallygiventhelimitedintraoperativeguidanceavailabletothesurgeon.Thisstudyevaluates
the feasibility of radioimmunoguided surgery (RIGS) to guide the detection and delineation of tumours intraoperatively. The
3D point-response function of a commercial gamma-ray-detecting probe (GDP) was determined as a function of radionuclide
(131I, 111In,99mTc), energy-window threshold, and collimator length (0.0–3.0-cm). This function was used to calculate the
minimum detectable tumour volumes (MDTVs) and the minimum tumour-to-background activity concentration ratio (T:B)
for eﬀective delineation of a breast tumour model. The GDP had larger MDTVs and a higher minimum required T:B for tumour
delineation with 131I than with 111In or 99mTc. It was shown that for 111I nt h e r ew a sab e n e ﬁ tt ou s i n gac o l l i m a t o rl e n g t ho f
0.5-cm. For the model used, the minimum required T:B required for eﬀective tumour delineation was 5.2 ± 0.4. RIGS has
the potential to signiﬁcantly improve the accuracy of breast-conserving surgery; however, before these beneﬁts can be realized,
novel radiopharmaceuticals need to be developed that have a higher speciﬁcity for cancerous tissue in vivo than what is currently
available.
1.Introduction
In North America, over 60% of breast cancer patients receive
breast-conserving surgery [1]. The primary goal of this
operativeprocedureisthecompleteexcisionofthecancerous
lesion, with a margin of grossly normal tissue. The purpose
of this margin is to reduce the probability that microscopic
disease remains. A secondary, conﬂicting goal is to limit the
volume of normal tissue that is excised, thereby reducing
patient morbidity and improving cosmesis. Achieving these
goals is technically challenging, and incomplete excision
occurs in 15–40% of breast-conserving operations, with
pathologic evaluation revealing cancerous cells at the cut
edge of the excised volume [2, 3]. Studies by Park et al.
[4]a n dP e t e r s o ne ta l .[ 5] have independently shown that
tumours with diameters greater than 2cm have a higher
likelihood of involved margins than smaller tumours. This
may be attributed to the presence of nonpalpable disease
at the boundaries of these tumours. This largely intra-
ductal disease is diﬃcult to detect using currently available
guidance techniques that rely on anatomical diﬀerences
between normal tissue and tumour [2, 6].
There is currently only limited intraoperative guidance
available for breast procedures. For palpable tumours, the
palpable edge is used to guide the complete excision of the
tumour. For nonpalpable tumours, wire localization is the
standard procedure. During wire placement, radiographic
images are obtained to guide the surgeon; however, the wire
may shift position within the breast, providing misleading
information about the tumour location at the time of breast-
conserving surgery. Additionally, the wire only marks the
approximate location of the centre of the gross tumour
within the breast and provides no information as to its
extent. Competing techniques to wire localization are being
developed; these techniques include radioguided occult
lesion localization (ROLL) and radioactive seed localization2 International Journal of Molecular Imaging
Table 1: Published tumour-to-background activity concentration
ratios achieved for radiopharmaceuticals used to target TAAs in
breast cancer.
Tumour-associated antigen
Tumour-to-
background activity
(T:B)
Reference
111In-B72.3 (TAG-72) 4.3 ±0.91i [15]
111In-Trastuzumab (HER-2) 1.3 −9.3ii [19]
111In-DTPA-
Trastuzumab Fab (HER-2) 25.2 ±1.62iii [16]
111In-benzyl-DOTA-Z (HER-2) 17 ±2.3iii [17]
131I-CEA antibody 1.4 ±0.3ii [21]
iT:Bratiowasdeterminedusingwellchambermeasurementsofnormaland
cancerous tissue uptake in a series of mastectomy samples. iiT:B ratio was
determinedbygammacameraimagingofpatientsenrolledinaclinicaltrial,
evaluating the tissue uptake in cancerous lesions and in background.iiiT:B
ratio was determined using well chamber measurements of normal and
cancerous tissue uptake from xenografted sacriﬁced mice.
(RSL). Radiographic or sonographic guidance is used to
inject a 99mTc labelled nanocolloidal tracer peritumorally in
the case of ROLL or implant an 125I brachytherapy seed at
the center of the nonpalpable tumour in the case of RSL.
The surgeon then uses a hand-held gamma-ray-detecting
probe (GDP), to guide the excision of the tumour [7–
11]. Ultrasonography has been explored as an alternative
approach; however, patients with tumours having extensive
intraductal disease or a predominantly inﬁltrative growth
pattern are not candidates for ultrasound-guided excision
[12–14].
Radioimmunoguided surgery (RIGS) diﬀerentiates nor-
mal and cancerous tissues by exploiting the functional status
ofcancerouscells.Onesuchfunctionalpropertyisthedegree
of overexpression of tumour-associated antigens (TAAs).
Thus, a targeting vehicle speciﬁc to TAAs, such as a mono-
clonal antibody or an antibody fragment, can be conjugated
to a radioactive label to create a radiopharmaceutical that
molecularly targets cancerous tissues. For RIGS of breast
cancer, TAAs that have been targeted by radiopharmaceu-
ticals include tumour-associated glycoprotein-72 (TAG-72)
[15], human epidermal growth factor-2 (HER-2) [16, 17],
and carcinoembryonic antigen (CEA) [18–23]. Table 1 lists
a sample of the radiopharmaceuticals that have been used to
target TAAs in breast cancer.
The clinical utilization of radioimmunoguidance involv-
estheadministrationofaradiolabelledmonoclonalantibody
or antibody fragment two hours to several days prior to
the breast-conserving surgery. This allows suﬃcient time
for the radiopharmaceutical to distribute throughout the
patient and attach preferentially to the TAAs overexpressed
on cancer cells. At the time of the surgery, prior to making
an incision and with the patient in the appropriate position,
the surgical oncologist takes a measurement of normal
background activity using GDP. The GDP is then used to
detect the tumour, which is where the measured count rates
aresigniﬁcantlygreaterthannormalbackgroundcountrates.
By taking measurements along the skin surface, moving
outward from the centre of the tumour, the surgeon can
delineate tumour extent as the point where measured count
rates are no longer signiﬁcantly higher than background.
In this study, we address two fundamental issues that
arise when considering the potential eﬃcacy of RIGS. The
ﬁrst is that there is currently no reference minimum T:B to
determine if a radiopharmaceutical would be a promising
candidate. The T:B for a particular radiopharmaceutical is a
function of several parameters such as its tumour-targeting
ability, tumour perfusion, and normal tissue clearance [24,
25]. The second issue is that there is no consensus regarding
which the optimum combination of device parameters for
RIGS is. The two main components of a RIGS system that
aﬀect its performance and are within the control of the
user are the radiopharmaceutical and the GDP. Important
study parameters related to the radiopharmaceutical include
the radionuclide used to label the targeting agent and the
amount of activity administered to the patient. Important
study parameters related to the GDP that aﬀect its sensitivity
and spatial resolution include the characteristics of the
collimator, the degree of scattered radiation that is rejected
by the device, and the measurement time. There is currently
little relevant information in the literature on the technical
requirements for optimizing RIGS for breast cancer.
This study reports on the results of a systematic phan-
tom-based evaluation of the impact of various critical
parameters (radionuclide, background activity concentra-
tion, measurement time, collimator length, energy-window
threshold) on the minimum detectable tumour volume
(MDTV) and comments on the feasibility of using RIGS for
tumour detection and delineation during breast-conserving
surgery.
2. Methods
2.1. Experimental Apparatus and Setup. The apparatus used
fortheexperimentsconsistedoftheC-Traksurgicalguidance
system (Care Wise Medical Products Corporation, Califor-
nia), with a 3.0cm long and 1.0cm diameter cylindrical
NaI(Tl) crystal. A simple side shield was manufactured in-
house as a 1.5cm thick, 3.6cm long hollow cylinder made of
lead, so that design speciﬁcations could be controlled during
thestudy.Itwasconstructedtoﬁttightlyaroundthesensitive
end of the GDP and completely shielded the NaI(Tl) crystal
except for the open face. The thickness of the side shield was
chosen such that the penetration was limited to less than 5%
at energies up to 364keV. The side shield was designed to
limit interference from photons emitted outside the nominal
ﬁeld of view of the detector. The face of the side shield was
constructed so that it would be ﬂushed with the sensitive end
of the GDP; consequently, it did not provide any additional
collimation. The GDP and the side shield were centred on a
water tank phantom and were used to acquire the sensitivity
map of a GDP that has robust side shielding, with 0.0cm of
additional collimation (Figure 1(a)).Within the water tank, a
radioactivesourcecouldbetranslatedhorizontallyanddepth
wise with respect to the probe position, with a translational
precisionof0.5mm.Awatertankwasusedtosimulateinthe
GDP sensitivity measurements the eﬀect of photon scatter
and attenuation expected in the breast.International Journal of Molecular Imaging 3
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Figure 1: The experimental apparatus used to acquire the point-response function of the GDP for each radionuclide. (a) Photograph C-
Trak NaI (Tl) probe (3cm long, 1cm diameter cylindrical crystal). Diagram of lead collimator 1.5cm thick and 3.6cm in length. (b) 8mm3
source (circled in blue) in a water tank. The source can be displaced horizontally or in depth with 0.5mm resolution.
The radioactive source was composed of a polymethyl
methacrylate capsule with a cavity in the shape of a 2×2mm
cylinder ﬁlled with radionuclide. The radioactive source was
constructed to be of similar diameter to that of milk ducts
found in the breast [26]. The wall thickness of the capsule
was 1mm. The three radionuclides used in this evaluation
were
99mTc, 111In, and 131I. These radionuclides are common
radiolabels that have been proposed for use in RIGS [22, 27].
Each radionuclide emits gamma-rays of diﬀering energies,
allowing a range of photon energies to be evaluated,
99mTc
(140keV, 89%), 111In (171keV, 90%; 245keV, 94%), and 131I
(364keV, 90%) [27].
The point-response function of the GDP was measured
in the water tank phantom for each of the three radionu-
clides. The sources were moved to a total of 352 positions
in a 2D plane, in three overlapping grids: a ﬁne grid with a
2mm spacing used for the region closest to the GDP where
the sensitivity changes rapidly and coarser grid spacings of
5mm and 10mm successively further away from the GDP.
The total region covered was 70mm horizontally by 130mm
in depth. For each source position, an energy spectrum was
acquired using a multichannel analyzer. A similar technique
for characterizing probe response has been used by Kwo et al.
[28] for only a single radionuclide 57Co.
To generate energy-dependent 2D point-response func-
tions,anenergy-windowthresholdwasappliedtothespectra
at each source position. The energy-window thresholds to
be evaluated were determined by dividing an energy range
(from the Compton backscatter peak to three standard
deviations past the photopeak) into ten evenly spaced inter-
vals. The energy ranges that were investigated for each
radionuclide were as follows:
99mTc (90–200keV), 111In
(100–350keV), and 131I (150–460keV). Photons detected
with energies below the Compton backscatter peak are more
likely to be a result of multiple scatters in the patient rather
than in the detecting crystal and may also arise from the
characteristic X-rays emitted from the lead collimator, which
contain no useful positional information, thus making the
backscatter peak a suitable starting point for the energy
range. The collimator response was then calculated and
applied to the 2D point-response function, based on the
formalism described by Barrett and Swindell [29]. The
calculated collimator response assumed that the collimator
was a perfect absorber and did not account for scattering
that may occur within the collimator. A 3D point-response
function for the GDP was generated by rotating the 2D
map around the central axis of rotational symmetry for the
GDP. The 3D point-response function could then be used to
calculate the response of the GDP to any activity distribution
for a particular radionuclide, energy-window threshold, and
collimator length.
The 3D point-response function was validated experi-
mentally by taking measurements of the radioactivity emit-
ted by the capsule point source at 1cm intervals along the
horizontal axis, at a consistent depth of 1cm, with a ﬁxed
collimatorlengthof0.5cmandtheenergy-windowthreshold
at Compton back scatter peak. This procedure was repeated
for each of the radionuclides used in this study.
2.2. Minimum Detectable Tumour Volume (MDTV). Current
re-excision rates are 15–40%, which can be used as an esti-
mate of the false-negative rates associated with lumpectomy
procedures [2, 3]. If a RIGS technique could reduce this
value, this would be of signiﬁcant beneﬁt to patients. This
study asks whether or not it is possible for a RIGS technique
to reduce the false-negative rate to 5%, which would be a
signiﬁcant improvement over what is currently achievable
clinically. The number of counts that need to be detected
in order to achieve a 5% false-negative and 5% false-positive
rategivenanestimatedbackgroundactivitycanbecalculated
usingtheformalismdescribedbyCurrie[30].Thenumberof
counts above the mean background count that corresponds
to a 5% false-positive and false-negative rates is referred to as
the ap r i o r idetection limit LD:
LD = 2.71 + 4.65

μB,( 1 )
where μB is the mean number of counts measured for
normalbackgroundtissue.Inasimulationifatumourmodel4 International Journal of Molecular Imaging
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Figure 2: These ﬁgures illustrate the iterative growth of the tumour volume used to determine MDTV. (a) Stage 1: the grey disc represents
the tumour volume, seen here growing horizontally to a maximum of 4cm in diameter. (b) Stage 2: two new layers, each 2mm thick, have
been added vertically to the tumour volume, and horizontal growth will occur only in these new layers to a maximum of 4cm in diameter.
This process continues to a maximum length of 4cm.
generated counts equal to or greater than the detection limit
+ mean background counts, the speciﬁcity and sensitivity
would be 95% for detecting tumours of that size [30].
Thebulkofthenormalbackgroundactivitywasassumed
to arise from the blood supply within the breast (given that
the radiopharmaceutical was administered intravenously).
This was not an ideal model as it did not incorporate
nonspeciﬁc distribution of the radiopharmaceutical within
the interstitium. However, nonspeciﬁc distribution is poorly
characterized in the literature and, in the absence of rel-
evant clinical data, the foregoing phantom geometry is
likely a reasonable approximation of that encountered in
vivo. A practical range of background activity concentra-
tion from 1 −5kBq/ml was used in this study [15, 20,
22]. The background activity concentration of breast tis-
sue was calculated by multiplying the background activ-
ity concentration by the volume of blood within breast
tissue (0.0336 ±0.006mL of blood/mL of tissue)[ 31].
Using a computer simulation, the modelled tumour vol-
ume was iteratively increased in size and the detected counts
were calculated. The point at which the expected counts
exceeded the detection limit determined the MDTV for that
combination of input parameters. The modelled tumour
volume was increased using a region-growing technique that
resulted in horizontal growth of the tumour prior to vertical
growth (Figure 2). This represented a diﬃcult scenario for a
particular tumour volume, that is, a broad, ﬂat tumour. In
contrast, an algorithm in which a tumour grows horizontally
and vertically simultaneously, like a sphere, would result
in a smaller MDTV since the tumour would occupy a
region closer to the detector where it is most sensitive.
During BCS patients lay supine, which results in their entire
breast ﬂattening along with the cancerous lesion; therefore,
spherical models are unlikely to represent the shape of
tumours in vivo,a c c u r a t e l y .
2.3. Tumour Edge Delineation. Tumour edge delineation
experiments were conducted in silico to assess the ability of
the GDP to determine the edge of a tumour phantom in
a uniform background. To facilitate comparison of all of
the parameters being investigated, a simple tumour model
was created. Generating a tumour model that captures all
of the complexities of actual tumours is diﬃcult; however,
the model chosen in this study accounts for some of the
main features that are important to the task of RIGS for
lumpectomies [4, 5]. The tumour modelled had the shape
of an oblate spheroid, with a maximum diameter of 3cm
and a length of 2cm. This shape was chosen because it
tapers towards the edges of the tumour, which in turn
reduces the activity through the full thickness of the lesion
t o w a r d si t sp e r i p h e r y ,a sw o u l db ee x p e c t e di nr e a lt u m o u r s .
Additionally, whenpatients arelying supine on the operating
table, tumours tend to compress; therefore, a fully spheroidal
shape would be less realistic. The tumour was modelled at
a depth of 3cm, which is representative of a depth where
it is currently diﬃcult to delineate the edges of the disease
accurately by palpation. Measurements were taken assuming
an anterior approach along the skin surface, as would be
done in vivo.
Using this tumour model in conjunction with a uniform
background activity, a 3D activity distribution was created
for diﬀerent combinations of normal tissue activity (derived
from background activity concentrations) and tumour activ-
ity (derived from both normal tissue activity and T:B ratios).
The response of the GDP to each distribution was calculated
using the 3D point-response function discussed earlier. The
measured edge was determined as the distance from the
centre of the tumour model to the point where the calculated
countsfellbelowthedetectionlevel.Forarangeofcollimator
lengths, background activity concentrations, and energy-
window thresholds, the minimum T:B was determined thatInternational Journal of Molecular Imaging 5
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Figure 3: The eﬀect of increasing the lower energy-window threshold on the sensitivity maps for (a)
99mTc, (b) 111In, and (c) 131I. The
lowest threshold was placed at the Compton backscatter peak for each radionuclide, and the upper threshold was placed at three standard
deviations (derived by ﬁtting a Gaussian distribution to the photopeak of the energy spectrum) above the photopeak. The top left corner of
each image corresponds to a sensitivity measurement directly in front of the centre of the GDP, while the lower right corner of each image
corresponds to a depth of 13cm and a horizontal displacement of 7cm.
resulted in the location of the measured edge corresponding
to the true edge of the tumour model. This represented the
point where the GDP was able to accurately delineate the
edge of the tumour model.
3. Results
3.1. Validation of the 3D Point-Response Function. The cal-
culated 3D point-response function was experimentally
validated by measuring the sensitivity proﬁle of the C-Trak
GDP at 1cm depth, with a physical collimator that had a
length of 0.5cm and the energy-window threshold at the
Comptonbackscatterpeakforeachoftheradionuclidesused
inthisstudy.Themaximumdeviationbetweenthecalculated
sensitivity proﬁle and the measured proﬁle was 3.4%,
indicatingthatthemethodtogeneratethe3Dpoint-response
function was accurate and was suitable for evaluating the
physical parameters involved in RIGS.
3.2. Eﬀect of Energy-Window Threshold on MDTV. Figure 3
illustrates the impact of increasing the energy-window
threshold on the 2D sensitivity of the GDP for
99mTc,
111In, and 131I sources, respectively. From these ﬁgures, it
was observed that increasing the energy-window threshold
reduced the sensitivity of the GDP. The decrease in sensitiv-
ity, however, was greater in areas that are further away from
the central axis of the probe, where one would prefer the
GDP not be sensitive (since oﬀ-axis sensitivity of this type
would lead to poor spatial resolution).
Figure 4 shows that for all three radionuclides increasing
theenergy-windowthresholdincreasestheMDTV.Theerror
bars in Figure 4 are calculated by summing in quadrature
the Poisson noise in the sensitivity map measurements and
the variation in the volume of blood within breast tissue as
published in [31]. However, the error bars did not incorpo-
rate variations in T:B as this was one of the parameters being
evaluated (i.e., T:B).6 International Journal of Molecular Imaging
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Figure 4: The eﬀect of increasing the lower energy-window thresh-
old on the MDTV for 111In,
99mTc, and 131I. The T:B was ﬁxed at
5. 0.0cm collimation and a background activity concentration of
5kBq/ml were used during these calculations to isolate the eﬀect of
increasing energy-window threshold on the MDTV. The abscissa of
theplotcorrespondstothefractionoftheenergyrangethatisabove
the energy-window threshold (0 corresponds to the threshold at 3
σ above the photo peak and 1 corresponds to the threshold at the
Compton backscatter peak).
3.3. Eﬀect of Collimator Length on MDTV. Figure 5 illus-
trated the trend with which collimator length aﬀected 2D
sensitivity for
99mTc, which is representative of all three
radionuclides. These images display how increasing the col-
limator length decreases the ﬁeld of view, thereby improving
the spatial resolution of the system. As shown in Figure 5,
the maximum sensitivity decreases rapidly as collimator
length is increased. Figure 6 plots the eﬀect of increasing the
collimator length on the MDTV for all three radionuclides.
The increased collimator length places the detector further
away from the radioactivity, resulting in a decrease in the
sensitivity of the GDP in accordance with the inverse square
law.Thisisapparentintheparabolictrendsthatareobserved
in the MDTV curves for each of the three radionuclide.
The smallest MDTV for
99mTc and 131I occurred when
there was 0.0cm of additional collimation extending beyond
the sensitive face of the GDP. Similar trends were observed
for
99mTc when the tumour was placed at depths 1cm,
2cm, and 3cm, which veriﬁed that the relationship between
collimatorlengthandMDTVwasrelativelyunaﬀectedbythe
tumour depth. For 111In, the smallest MDTV occurred when
the collimator length was 0.5cm. Figure 6 shows that 111In
consistentlyhadthesmallestMDTV;however,thediﬀerences
in the smallest MDTV between 111In and
99mTc were not
statistically signiﬁcant.
3.4. Eﬀect of Background Activity Concentration on MDTV.
In Figure 7, it can be observed that the MDTV is inversely
proportional to the square root of the background activity
Table 2: Minimum T:B ± standard deviation to achieve tumour
edge delineation. Background activity concentration is a surrogate
for administered activity and can be related to relative error in GDP
measurements. The combinations of parameters resulting in the
optimum overall performance and used to generate the data in this
table are as follows: for 111In, a 100keV energy-window threshold
anda0.5mmcollimatorlength;for
99mTc,a90keVenergy-window
threshold and 0.0cm collimation; and for 131I, a 150keV energy-
window threshold and 0.0cm collimation.
Radionuclide
Background activity concentration
1
kBq/mL
2
kBq/mL
3
kBq/mL
4
kBq/mL
5
kBq/mL
99mTc 14.4±1.1 10.0±0.8 8.1±0.6 7.0±0.5 6.2±0.5
111In 11.9±0.9 8.3±0.7 6.7±0.6 6.0±0.6 5.2±0.4
131I 28.3±2.2 19.4±1.5 15.6±1.2 13.4±1.0 12.0±0.9
concentration. As the background activity concentration is
increased, the slope of the MDTV curve decreases. The error
bars in Figure 7 are calculated by summing in quadrature
the Poisson noise in the sensitivity map measurements and
the variation in the volume of blood within breast tissue as
published in [31]. Under these experimental conditions, a
background activity concentration below 3kBq/mL signiﬁ-
cantly increases the MDTV compared to a background activ-
ity concentration of 5kBq/mL. Both
99mTc and 111In have
statistically superior performances to 131Ia ta l lb a c k g r o u n d
activity concentrations (P<0.05). There also appears to be
no signiﬁcant diﬀerence between the performance of
99mTc
and 111In.
3.4.1. Tumour Edge Delineation. For each combination of
collimator length and energy-window threshold, the mini-
mum T:B required for tumour edge delineation was deter-
mined at increasing background activity concentrations for
each radionuclide. In this fashion, the eﬀect of the combina-
tion of all of these parameters on tumour edge delineation
was determined.
The parameters used to generate Table 2 resulted in the
best performance of all combinations evaluated and were
as follows: for 111In, a 100keV energy-window threshold
and a 0.5mm collimator length; for
99mT c ,a9 0 k e V
energy-window threshold and 0.0cm collimation; for 131I,
a 150keV energy-window threshold and 0.0cm collimation.
ThelowestT:Bsobtainedwere6.2±0.5for
99mTc,5.2±0.4for
111In, and 12.0±0.9f o r131I. All were obtained at the highest
background activity concentration modelled of 5kBq/mL.
From Table 2, it is apparent that 111In and
99mTc can be used
to accurately delineate the tumour edge at all background
activity concentrations at signiﬁcantly lower T:Bs than is
possible with 131I. In addition, there is a trend for 111In
to have the lowest required T:B of the three radionuclides
evaluated.
4. Discussion
In order to evaluate the feasibility of RIGS of breast cancer,
the optimum system parameters were determined. This wasInternational Journal of Molecular Imaging 7
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Figure 6: The eﬀect of increasing the collimator length on the
MDTV for 111In,
99mTc, and 131I. The T:B was ﬁxed at 5, the
background activity concentration was ﬁxed at 5kBq/ml, the lowest
energy-window threshold was applied for each radionuclide, while
the collimator length was increased from 0 to 3cm in increments of
0.5cm. The error bars in this plot were calculated by summing in
quadrature the Poisson noise in the sensitivity map measurements
and the variation in the volume of blood within breast tissue [31].
found to be an 111In radiolabel for the highest background
activity concentration evaluated (5kBq/mL), a collimator
lengthof0.5cm,andanenergywindowthresholdof100keV,
for detecting tumours in a uniform background at a depth
of 3cm. A tumour must be greater than 8.7 ± 2cm 3
(corresponding to a diameter of 2.5 ± 0.2cm) to reduce re-
excision rates from their current levels of 15–40% [2, 3]t o
5% using RIGS at a clinically achievable T:B of ∼5[ 15].
Radiolabel:
99mTc. As expected, the C-Trak GDP was
more sensitive to 111In and
99mTc than to 131I. The reason
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Figure 7: The eﬀect of increasing the background activity concen-
tration on the MDTV for 111In,
99mTc, and 131I. T:B was ﬁxed at 5,
0.0cm collimation was used, and the entire energy range was used
for acquisitions.
for this was the lower eﬃciency of the NaI(Tl) crystal used
in the C-Trak GDP for the 364keV photons emitted by 131I.
Barber et al. [32] have shown that scintillation crystals such
as NaI(Tl) are more sensitive than semiconductor crystals
such as CZT and CdTe at the photon energies used in this
study. The higher sensitivity for 111In and
99mTc compared
to 131I, therefore, should also be true for other commercially
available GDPs. This study has shown that an 111In label
results in the best performance; however, a counterintuitive
ﬁnding from this study is that 111In and
99mTc perform
similarly when variations in blood volume within breast tis-
sue are incorporated into the phantom model. For example,8 International Journal of Molecular Imaging
similar-sized tumours may be detected by using
99mTc in a
patient who has a high activity concentration in their blood
as compared to using 111In in a patient with a low activity
concentration in their blood. As 111In emits two photons, it
would be expected to produce more counts per unit activity,
which due to Poisson statistics would reduce the relative
error in each measurement compared to
99mTc. However,
the two photons emitted by 111In diﬀer in energy (171keV
and 245keV), and the eﬃciency of the GDP for the 245keV
photon is low (75% of the eﬃciency for the 171keV photon
using a NaI(Tl) crystal 3cm thick). Therefore, the overall
beneﬁt of having two photons per decay is diminished.
Higherbackgroundactivityconcentrationsof
99mTc-labelled
radiopharmaceuticals can be achieved for the same patient
radiationsdoseascomparedto 111In.Thus,itmaybepossible
to detect smaller tumour volumes using
99mTc. The half-
life of
99mTc (6 hours), however, is much shorter than that
of 111In (2.83 days), limiting the use of
99mTc to targeting
agents that have rapid clearance from the blood stream.
Background Activity Concentration: 5 kBq/mL. An in-
crease in this parameter was assumed to cause proportional
increases in normal-tissue background and in tumour activ-
ity concentrations. Under these conditions, it was demon-
strated that the MDTV is inversely proportional to the
square root of the background activity concentration for the
assumed tumour model. As stated previously, background
activity was assumed to relate directly to administered
activity. In principle, the higher the lesion activity, which is
associated with a higher background activity, the lower the
statisticaluncertaintyinthemeasuredcountrates.Thislower
statistical uncertainty in turn helps to reduce the minimum
detectable tumour volume. This suggests that administer-
ing more activity will result in the detection of smaller
tumours, as was expected. In principle, the background
activity concentration can be translated into administered
activity for any radiopharmaceutical, taking into account its
speciﬁc elimination pharmacokinetics. The radiation dose
to the patient per unit of injected activity depends on
the radionuclide and the pharmacokinetics of the agent
involved. Assuming similar kinetics, the eﬀective dose per
unit administered activity dose for
99mTc is considerably
lower than those for 111In (which emits photons and
Auger electrons) and 131I (which emits photons and beta
particles). Since lower radiation doses to the patient would
be expected for
99mTc compared to 111In and 131I, it may
be possible to administer more activity to patients by using
a
99mTc radiolabel; therefore, a higher background activity
concentration can be achieved. Of course, 111In’s long half-
life has the advantage of allowing greater time for clearance
of nonspeciﬁc uptake than does
99mTc’s short half-life.
Collimator Length: 5mm. The lowest MDTV using 111In
resulted when a 5mm long collimator was used, whereas
for
99mTc and 131I 0.0cm collimation was required. Further
investigation of 111In showed that the increase in collimation
decreases the number of photons from outside the ﬁeld of
view that penetrate the lead shielding of the GDP and are
incorrectly detected. For 111In, 2mm of lead is required to
stop 95% of the 171keV photons, while the 245keV photons
require 5mm of lead. A 5mm extension of the collimator is,
therefore, required to provide adequate absorption of both
photon energies and may explain why 5mm collimation
resulted in the lowest MDTV for 111In. For
99mTc, 1.2mm
of lead is required to stop 95% of the 140keV photons.
The impact of a collimator extension of 1.2mm could not
be evaluated using the 3D point-response function since it
had a spatial resolution of 2mm. Due to the coarseness of
the 3D point-response function, it was found that 0.0cm
collimation was better than a 2mm collimator length. For
131I ,1 4 . 7m mo fl e a di sr e q u i r e dt os t o pt h e3 6 4k e Vp h o t o n s .
Since the sensitivity of the GDP is already low for these
photons, increasing the collimator length only degrades
performance by further decreasing the sensitivity of the
system. Changing the depth of the tumour from 1 to 3cm
did not alter the fact that increasing the collimator length,
beyond the length required to properly shield the GDP,
dramatically degraded the GDPs performance. Sensitivity of
the GDP seems to be the dominant factor in determining the
optimal performance of the system.
Energy-Window Threshold: Compton Backscatter Peak. In
RIGSthesensitivity of thesystemis more important thanthe
spatial resolution; as such, the lowest MDTV results when
the energy-window threshold was placed at the Compton
backscatter peak, indicating that the improved spatial reso-
lution from increasing the energy-window threshold did not
compensate for the decrease in sensitivity.
Tumour Edge Delineation: This evaluation determined
that a minimum T:B of 5.2 ± 0.4 is required in order to
delineate a 3cm diameter tumour from a uniform back-
ground using an 111In radiolabel, 5mm collimator length,
and a background activity concentration of 5kBq/mL. The
commonly held paradigm is that a long collimator with
no energy-window threshold, thereby a system with high
spatial resolution with the highest possible sensitivity, would
best suit this application. Our ﬁndings show that this is
not the case: the impact of collimation, while improving
spatial resolution, increases the separation of the probe from
the skin surface. This has two eﬀects: (1) sensitivity drops
dramatically due to inverse square law and (2) the change
in sensitivity with increasing distance becomes less dramatic
(Figure 5) resulting in the probe becoming relatively more
sensitive to background radiation. Both of these properties
make the extended collimator undesirable for RIGS. While
it is true that with a 0.0cm collimator much of the gross
tumour will still be detected when the probe is positioned
at the tumour edge, the inverse square dropoﬀ in sensitivity
from the centre of the probe acts like a virtual collimator,
whilst still maintaining maximum possible sensitivity.
Gamma-rays emitted by the radiolabels that are used for
RIGS penetrate large thicknesses of tissue, and GDP readings
a r et h u sa d v e r s e l ya ﬀected by normal background counts
distal to the probe. Therefore, to distinguish a tumour from
background, the tumour must have a signal substantially
larger than that from surrounding normal tissues; that is, the
radiopharmaceutical must be more speciﬁc to the tumour.
Creating radiopharmaceuticals that selectively target cancer
cells, that do not bind to normal cells, and that have a rapid
clearance from the patient is technically challenging.International Journal of Molecular Imaging 9
More recently beta probes have been introduced as an
alternative to GDPs. The technique of beta particle detection
uses the short range of beta particles (on the order of mil-
limeters in tissue) to its advantage, by reducing the detected
signal from distant organs and tissues that would otherwise
confound a conventional GDP. Additionally, the short range
of beta particles precludes the need for collimation; thus,
sensitivity is retained. The beta particles emitted by 18F, a
commonly used radiolabel, have a range of 1-2mm in tissue.
This theoretically allows for localization of residual tumour
to within 1-2mm, making beta imaging probes potentially
well suited to evaluating the postsurgical cavity to ensure
clearance intraoperatively. This same property, however,
renders beta imaging probes unsuitable for intraoperative
tumour delineation, since the tumour would be excessively
deep [33–38].
5. Conclusion
There are at least two key limitations in the manner in
which potential radiopharmaceuticals for RIGS are currently
evaluated: (1) the most appropriate set of system parameters
has yet to be established; (2) no minimum T:B has been
suggested as being required to determine whether a radio-
pharmaceutical is likely to be a good candidate for use in
RIGS. The results reported in this study have shown that
the most appropriate combination of parameters included
a
99mTc radiolabel with 0.0cm collimation and minimal
energy-window thresholding or 111In with a collimator
length of 0.5cm. Additionally, it was shown that a T:B of at
least 5.2 ± 0.4 is required to accurately delineate the tumour
edge of a 3cm diameter lesion from a simple uniform
background. Therefore, the role of RIGS for guidance of
breast-conserving procedures is promising; however, novel
radiopharmaceuticals need to be developed that have a
higher speciﬁcity for cancerous tissue in vivo than what is
currently available.
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